Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons

Journal of Infectious Diseases

Volumn 179, Issue 4, 1999, Pages 790-798

  Wit, Ferdinand W N M ^b   Van Leeuwen, Remko ^b   Weverling, Gerrit Jan ^b   Jurriaans, Suzanne ^b   Nauta, Klaas ^b   Steingrover, Radjin ^b   Schuijtemaker, Johan ^b   Eyssen, Xander ^b   Fortuin, David ^b   Weeda, Marjan ^b   De Wolf, Frank ^b   Reiss, Peter ^b   Danner, Sven A ^b   Lange, Joep M A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ANEMIA; ARTICLE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; MYALGIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; RISK FACTOR; TREATMENT FAILURE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV-1; HUMANS; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0004674209     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314675     Document Type: Article

References (22)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
3. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA panel. JAMA 1997;277:1962-9.
4. Hammer SM. Advances in antiretroviral therapy and viral load monitoring. AIDS 1996; 10(suppl 3):S1-11.
5. Gazzard BG, Moyle GJ, Weber J, et al. British HIV association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086-92.
6. Montaner JS, Hogg RS, O'Shaughnessy MV. Emerging international consensus for use of antiretroviral therapy. Lancet 1997;349:1042.
7. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997;315:1194-9.
8. Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11:F113-6.
9. Brodt HR, Kamps BS, Gute P, et al. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997;11:1731-8.
10. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS 1997;11:F101-5.
11. Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load driven antiretroviral therapy. AIDS 1998;12:279-84.
12. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998;279:450-4.
13. Centers for Disease Control. Update: trends in AIDS incidence - United States, 1996. MMWR Morb Mortal Wkly Rep 1997;46:861-7.
14. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998;12:F9-14.
15. Raboud JM, Montaner JS, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS 1998;12:1619-24.
16. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1993;41:1-19.
17. Committee on Channels of Regulation for AIDS-Treatment. Development of resistance with the use of HIV-inhibiting drugs. Rijswijk: Health Council of The Netherlands, 1998; publication no. 1998/07.
18. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
19. Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998;4:208-14.
20. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4 cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet 1998;351:723-4.
21. Cohen J. Failure isn't what it used to be ... but neither is success. Science 1998;279:1133-4.
22. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998;351:1682-6.